8.80Open8.80Pre Close0 Volume939 Open Interest4.00Strike Price0.00Turnover200.61%IV28.00%PremiumJan 17, 2025Expiry Date6.00Intrinsic Value100Multiplier22DDays to Expiry2.80Extrinsic Value100Contract SizeAmericanOptions Type0.9818Delta0.0090Gamma1.65Leverage Ratio-0.0053Theta0.0023Rho1.62Eff Leverage0.0011Vega
Omeros Stock Discussion
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
Omeros (OMER) announced successful results from its narsoplimab pivotal trial for treating transplant-associated thrombotic microangiopathy (TA-TMA). The primary statistical analysis showed that patients treated with narsoplimab had an over 3-fold reduction in mortality risk (hazard ratio = 0.32) compared to untreated p...
No comment yet